Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome

Schizophrenia Research

Volumn 85, Issue 1-3, 2006, Pages 124-131

  Rosen, Joanna L ^a   Miller, Tandy J ^a   D'Andrea, Jennifer T ^a   McGlashan, Thomas H ^a   Woods, Scott W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Comorbidity; Early intervention; Prodrome; Scale of Prodromal Symptoms (SOPS); Schizophrenia

Indexed keywords

ADJUSTMENT DISORDER; ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; CANNABIS ADDICTION; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; CHILD; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 33745377106     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.03.034     Document Type: Article

References (38)

1. Amminger G.P., Pape S., Rock D., Roberts S.A., Ott S.L., Squires-Wheeler E., Kestenbaum C., and Erlenmeyer-Kimling L. Relationship between childhood behavioral disturbance and later schizophrenia in the New York High-Risk Project. Am. J. Psychiatry 156 4 (1999) 525-530
2. an der Heiden W., and Hafner H. The epidemiology of onset and course of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 250 6 (2000) 292-303
3. Buckley P.F. Substance abuse in schizophrenia: a review. J. Clin. Psychiatry 59 Supplement 3 (1998) 26-30
4. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., and Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 57 10 (2005) 1117-1127
5. Cassano G.B., Pini S., Saettoni M., Rucci P., and Dell'Osso L. Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J. Clin. Psychiatry 59 2 (1998) 60-68
6. Chapman L.J., Chapman J.P., Kwapil T.R., Eckblad M., and Zinser M.C. Putatively psychosis-prone subjects 10 years later. J. Abnorm. Psychology 103 2 (1994) 171-183
7. Davidson J.R.T., Hughes L.D.L., George L.K., and Blazer D.G. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol. Med. 23 3 (1993) 709-718
8. Dixon L., Haas G., Weiden P.J., Sweeney J., and Frances A.G. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 148 2 (1991) 224-230
9. Fenton W.S. Comorbid conditions in schizophrenia. Curr. Opin. Psychiatr. 14 1 (2001) 17-23
10. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0) (1996), Biometrics Research Department, New York State Psychiatric Institute, New York
11. Green A.I., Canuso C.M., Brenner M.J., and Wojcik J.D. Detection and management of comorbidity in patients with schizophrenia. Psychiatr. Clin. North Am. 26 1 (2003) 115-139
12. Hafner H., Hambrecht M., Loffler W., Munk-Jorgenson P., and Riecher-Rossler A. Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle. Psychol. Med. 28 2 (1998) 351-365
13. Hafner H., Maurer K., Loffler W., an der Heiden P., Monk-Jorgensen P., Hambrecht M., and Riecher-Rossler A. The ABC schizophrenia study: a preliminary overview of the results. Soc. Psychiatry Psychiatr. Epidemiol. 33 8 (1998) 380-386
14. Hawkins K.A., McGlashan T.H., Quinlan D., Miller T.J., Perkins D.O., Zipursky R.B., Addington J., and Woods S.W. Factorial structure of the Scale of Prodromal Symptoms. Schizophr. Res. 68 2-3 (2004) 339-347
15. Kovasznay B., Fleischer J., Tanenberg-Karant M., Jandorf L., Miller A.D., and Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr. Bull. 23 2 (1997) 195-201
16. Lencz T., Smith C.W., Auther A., Correll C.U., and Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 68 1 (2004) 37-48
17. McGlashan T.H., and Fenton W.S. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr. Bull. 19 1 (1993) 71-84
18. McGlashan T.H., Miller T.J., Woods S.W., Hoffman R.E., and Davidson L.D. Instrument for the assessment of prodromal symptoms and states. In: Miller T., Mednick S., McGlashan T., Libiger T., and Johannessen J. (Eds). Early Intervention in Psychotic Disorders (2001), Kluwer Academic Publishers, Amsterdam 135-149
19. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T.J., Woods S.W., Hawkins K.A., Hoffman R., Lindborg S., Tohen M., and Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of bring prodromally symptomatic for psychosis: I. Study rationale and design. Schizophr. Res. 61 (2003) 7-18
20. Meyer S.E., Bearden C.E., Lux S.R., Gordon J.L., Johnson J.K., O'Brien M.P., Niendam T.A., Loewy R.L., Ventura J., and Cannon T.D. The psychosis prodrome in adolescent patients viewed through the lends of DSM-IV. J. Child Adolesc. Psychopharmacol. 15 3 (2005) 434-451
21. Miller T.J., McGlashan T.H., Woods S.W., Stein K., Driesen N., Corcoran C.M., Hoffman R., and Davidson L. Symptom assessment in schizophrenic prodromal states. Psychiatr. Q. 70 4 (1999) 273-287
22. Miller T.J., McGlashan T.H., Rosen J.L., Somjee L., Markovich P.J., Stein K., and Woods S.W. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry 159 5 (2002) 863-865
23. Miller T.J., McGlashan T.H., Rosen J.L., Cadenhead K., Ventura J., McFarlane W., Perkins D.O., Pearlson G.D., and Woods S.W. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 29 4 (2003) 703-715
24. Miller T.J., Zipursky R.B., Perkins D., Addington J., Woods S.W., Hawkins K.A., Hoffman R., Preda A., Epstein I., Addington D., Lindborg S., Marquez E., Tohen M., Breier A., and McGlashan T.H. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of bring prodromally symptomatic for psychosis: II. Baseline characteristics of the "prodromal" sample. Schizophr. Res. 61 (2003) 19-30
25. Moller P., and Husby R. The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior. Schizophr. Bull. 26 1 (2000) 217-232
26. Poulton R., Caspi A., Moffitt T.E., Cannon M., Murray R., and Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch. Gen. Psychiatry 57 11 (2000) 1053-1058
27. Preda A., Miller T.J., Rosen J.L., Somjee L., McGlashan T.H., and Woods S.W. Treatment histories of patients with a syndrome putatively prodromal for schizophrenia. Psychiatr. Serv. 53 3 (2002) 342-344
28. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. J. Am. Med. Assoc. 264 19 (1990) 2511-2518
29. Rosen J.L., Woods S.W., Miller T.J., and McGlashan T.H. Prospective observations of emerging psychosis. J. Nerv. Ment. Dis. 190 3 (2002) 133-141
30. Strakowski S.M., Tohen M., Stoll A.L., Faedda G.L., Mayer P.V., Kolbrener M.L., and Goodwin D.C. Comorbidity in psychosis at first hospitalization. Am. J. Psychiatry 150 5 (1993) 752-757
31. Turnbull G., and Bebbington P. Anxiety and the schizophrenic process: clinical and epidemiological evidence. Soc. Psychiatry Psychiatr. Epidemiol. 36 5 (2001) 235-243
32. Tyrer P., Gunderson J., Lyons M., and Tohen M. Extent of comorbidity between mental state and personality disorders. J. Pers. Disord. 11 13 (1997) 242-259
33. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., and Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 156 4 (2002) 319-327
34. Woods S.W., Breier A., Zipursky R.B., Perkins D.O., Addington J., Miller T.J., Hawkins K.A., Marquez E., Lindborg S., Tohen M., and McGlashan T.H. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol. Psychiatry 54 (2003) 453-464
35. Yung A.R., and McGorry P.D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 22 2 (1996) 353-370
36. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., and McGorry P.D. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 60 1 (2003) 21-32
37. Zammit S., Allebeck P., Andreasson S., Lundberg I., and Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325 (2002) 1199-1201
38. Zanarini M.C., Frankenburg F.R., Chauncey D.L., and Gunderson J.G. The Diagnostic Interview for Personality Disorders: interrater and test-retest reliability. Compr. Psychiatry 28 6 (1987) 467-480